S Shahzad Mustafa

Dr. S Shahzad Mustafa

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
SMS Shahzad Mustafa
S Shahzad Mustafa
KCKelly Conn
Kelly Conn
ARAllison Ramsey
Allison Ramsey

18 January 2023 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Closed access
SMS Shahzad Mustafa
S Shahzad Mustafa

23 September 2020 in American Journal of Rhinology & Allergy
Verified
Journal Article
Closed access
PDF file
SMS Shahzad Mustafa
S Shahzad Mustafa
KVKarthik Vadamalai
Karthik Vadamalai
BSBryan Scott
Bryan Scott
ARAllison Ramsey
Allison Ramsey
Background: Aspirin-exacerbated respiratory disease (AERD) affects 7% of asthmatics. Usual therapies are inadequate for asthma and/or nasal polyposis, leading to decreased quality of life. Objective: Our objective was to evaluate the efficacy of dupilumab in AERD patients with uncontrolled, chronic rhinosinusitis with nasal polyposis (CRSwNP). Methods: Patients 18 years and older with a physician diagnosis of AERD and sino-nasal outcome test 22 (SNOT 22) score ≥19 despite standard medical therapy were eligible for the study. Patients received one month of placebo dosing, followed by 6 months of dupilumab. Patients were blinded to the order of therapy. Wilcoxon-paired rank sum test was used to compare study outcomes at baseline and the completion of the study. Results: Ten patients completed the study. The median baseline SNOT 22 score improved from 46 [IQR: 34 to 64.8] to 9.5 [IQR: 2.5 to 19] after 6 months of therapy (p = 0.0050). The median baseline Lund MacKay score improved from 21.5 [IQR: 17 to 23.3] to 4 [IQR: 1.2 to 6] after 6 months of therapy (p = 0.0050). There was also improvement in the following secondary outcomes: asthma control test (ACT), mini asthma quality of life questionnaire (AQLQ), and University of Pennsylvania Smell Identification test (UPSIT). Exhaled nitric oxide (FeNO), total serum IgE, 24-hour urinary leukotriene E 4 , and serum thymus and activation regulated cytokine (TARC) also decreased. There were no significant study-related adverse events. Conclusion: Dupilumab was highly effective as add-on therapy for CRSwNP in AERD, improving patient-reported outcomes, sinus opacification, and markers of T2 inflammation.

24 March 2018 in Current Allergy and Asthma Reports
Verified
Journal Article
Closed access
PDF file
SMS Shahzad Mustafa
S Shahzad Mustafa
DODavid Ostrov
David Ostrov
DYDaniel Yerly
Daniel Yerly

1 January 2022 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
SPSara Patrawala
Sara Patrawala
ARAllison Ramsey
Allison Ramsey
PCPeter Capucilli
Peter Capucilli
LTLinh-An Tuong
Linh-An Tuong
KVKarthik Vadamalai
Karthik Vadamalai
SMS Shahzad Mustafa
S Shahzad Mustafa

1 October 2020 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Closed access
SMS Shahzad Mustafa
S Shahzad Mustafa
LYLuanna Yang
Luanna Yang
MMMahta Mortezavi
Mahta Mortezavi
KVKarthik Vadamalai
Karthik Vadamalai
ARAllison Ramsey
Allison Ramsey